| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell, Tumor, and Stem Cell Biology |
1 Xenogen Corp., Alameda, California and 2 Xenogen Biosciences, Cranbury, New Jersey
Requests for reprints: Scott Lyons, Xenogen Corp., 860 Atlantic Avenue, Alameda, CA 94501. Phone: 510-291-6276; E-mail: scott.lyons{at}xenogen.com.
Several transgenic mouse models of prostate cancer have been developed recently that are able to recapitulate many key biological features of the human condition. It would, therefore, be desirable to employ these models to test the efficacy of new therapeutics before clinical trial; however, the variable onset and nonvisible nature of prostate tumor development limit their use for such applications. We now report the generation of a transgenic reporter mouse that should obviate these limitations by enabling noninvasive in vivo bioluminescence imaging of normal and spontaneously transformed prostate tissue in the mouse. We used an 11-kb fragment of the human prostate-specific antigen (PSA) promoter to achieve specific and robust expression of firefly luciferase in the prostate glands of transgenic mice. Ex vivo bioluminescence imaging and in situ hybridization analysis confirmed that luciferase expression was restricted to the epithelium in all four lobes of the prostate. We also show that PSA-Luc mice exhibit decreased but readily detectable levels of in vivo bioluminescence over extended time periods following androgen ablation. These results suggest that this reporter should enable in vivo imaging of both androgen-dependent and androgen-independent prostate tumor models. As proof-of-principle, we show that we could noninvasively image SV40 T antigen–induced prostate tumorigenesis in mice with PSA-Luc. Furthermore, we show that our noninvasive imaging strategy can be successfully used to image tumor response to androgen ablation in transgenic mice and, as a result, that we can rapidly identify individual animals capable of sustaining tumor growth in the absence of androgen. (Cancer Res 2006; 66(9): 4701-7)
This article has been cited by other articles:
|
|
 |
|
  N. Zhang, S. Lyons, E. Lim, and P. Lassota A Spontaneous Acinar Cell Carcinoma Model for Monitoring Progression of Pancreatic Lesions and Response to Treatment Through Noninvasive Bioluminescence Imaging Clin. Cancer Res., August 1, 2009; 15(15): 4915 - 4924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. T. Winnard Jr., A. P. Pathak, S. Dhara, S. Y. Cho, V. Raman, and M. G. Pomper Molecular Imaging of Metastatic Potential J. Nucl. Med., June 1, 2008; 49(Suppl_2): 96S - 112S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Kang and J.-K. Chung Molecular-Genetic Imaging Based on Reporter Gene Expression J. Nucl. Med., June 1, 2008; 49(Suppl_2): 164S - 179S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zheng, C.-n. Njauw, and M. Martins-Green A hCXCR1 transgenic mouse model containing a conditional color-switching system for imaging of hCXCL8/IL-8 functions in vivo J. Leukoc. Biol., November 1, 2007; 82(5): 1247 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-P. Liao, C. Zhong, G. Saribekyan, J. Bading, R. Park, P. S. Conti, R. Moats, A. Berns, W. Shi, Z. Zhou, et al. Mouse Models of Prostate Adenocarcinoma with the Capacity to Monitor Spontaneous Carcinogenesis by Bioluminescence or Fluorescence Cancer Res., August 1, 2007; 67(15): 7525 - 7533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Kaijzel, G. van der Pluijm, and C. W.G.M. Lowik Whole-Body Optical Imaging in Animal Models to Assess Cancer Development and Progression Clin. Cancer Res., June 15, 2007; 13(12): 3490 - 3497. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
